Ningbo Xixin Trading Co., LTD – Trademark Portfolio
Entity Type: 99
Ningbo Xixin Trading Co., LTD holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include ANFINSO and MAGICDRY. The owner is based in Ningbo City, Zhejiang.
Room 172
No. 755 Liyuan North Rd, Haishu District
Ningbo City, Zhejiang 315000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Ningbo Xixin Trading Co., LTD's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Ningbo Xixin Trading Co., LTD have?
Ningbo Xixin Trading Co., LTD has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending.
What trademark classes does Ningbo Xixin Trading Co., LTD file in?
Ningbo Xixin Trading Co., LTD files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Ningbo Xixin Trading Co., LTD's most well-known trademarks?
Ningbo Xixin Trading Co., LTD's registered trademark portfolio includes well-known marks such as ANFINSO and MAGICDRY. These are among 2 currently registered trademarks in the portfolio.
What is Ningbo Xixin Trading Co., LTD's trademark registration success rate?
Ningbo Xixin Trading Co., LTD has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 1 application is pending review.